DBV Technologies (France) Top Management
| DBV Stock | EUR 1.29 0.03 2.38% |
DBV Technologies employs about 85 people. The company is managed by 42 executives with a total tenure of roughly 255 years, averaging almost 6.0 years of service per executive, having 2.02 employees per reported executive. Analysis of DBV Technologies' management performance can provide insight into the company performance.
| MarieCatherine Therene CEO Deputy Chief Executive Officer and Responsible Pharmacist |
| Daniel Tasse CEO Chief Executive Officer, Director |
DBV |
DBV Technologies Management Team Effectiveness
The company has return on total asset (ROA) of (0.2178) % which means that it has lost $0.2178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4299) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.DBV Technologies Workforce Comparison
DBV Technologies SA is one of the top stocks in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 288. DBV Technologies totals roughly 85.0 in number of employees claiming about 30% of equities under Health Care industry.
DBV Technologies Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. DBV Technologies Price Series Summation is a cross summation of DBV Technologies price series and its benchmark/peer.
DBV Technologies Notable Stakeholders
A DBV Technologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as DBV Technologies often face trade-offs trying to please all of them. DBV Technologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting DBV Technologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Bertrand Dupont | Co-Founder and Sr. Executive VP of Technology | Profile | |
| MarieCatherine Therene | Deputy Chief Executive Officer and Responsible Pharmacist | Profile | |
| Daniel Tasse | Chief Executive Officer, Director | Profile | |
| PierreHenri Benhamou | Chairman of the Board, CEO | Profile | |
| Michel Rosen | Non-Executive Independent Chairman of the Board | Profile | |
| Joan Schmidt | Executive Vice President General Counsel | Profile | |
| Ramzi Benamar | Chief Financial Officer | Profile | |
| Sebastien Robitaille | Chief Financial Officer | Profile | |
| David Schilansky | COO | Profile | |
| Laurent Martin | Sr. Executive VP of Regulatory and Product Strategy | Profile | |
| Pascale Ehouarn | Industrial Development and Production Director | Profile | |
| Claude Thebault | Medical Director | Profile | |
| Viviane Monges | Non-Executive Independent Director | Profile | |
| Claire Giraut | Non-Executive Independent Director | Profile | |
| Didier Hoch | Director | Profile | |
| Daniel Soland | Non-Executive Independent Director | Profile | |
| Julie ONeill | Non-Executive Director | Profile | |
| Nathalie Donne | Director of Bus. Devel. and Corporate Communication | Profile | |
| Lucie Mondoulet | Director of Research | Profile | |
| Chahra Louafi | Director - Representative of CDC Entreprises (Innobio) | Profile | |
| Peter Hutt | Independent Director | Profile | |
| Rafaele Tordjman | Director - Representative of Sofinnova Partners | Profile | |
| Rafale Tordjman | Director - Representative of Sofinnova Partners | Profile | |
| George Horner | Director | Profile | |
| Michael Goller | Non-Executive Director | Profile | |
| Torbjorn Bjerke | Non-Executive Independent Director | Profile | |
| Torbjrn Bjerke | Independent Director | Profile | |
| Mailys Ferrere | Non-Executive Director | Profile | |
| Wence Agbotounou | Chief Clinical Trial Officer | Profile | |
| Caroline Daniere | Chief Human Resource Officer | Profile | |
| Adam Slatter | Chief Quality Officer | Profile | |
| Daniel Tass | CEO Director | Profile | |
| Hugh Sampson | Chief Scientific Officer | Profile | |
| Pascal Wotling | Chief Technical Operations Officer | Profile | |
| Charles Ruban | Chief Development Officer | Profile | |
| Anne Pollak | Head Relations | Profile | |
| Michele Robertson | Chief Legal Officer | Profile | |
| Joseph Becker | VP Communications | Profile | |
| Sbastien Robitaille | Chief Officer | Profile | |
| Veronique Foutel | Chief Strategic Marketing Officer | Profile | |
| Pharis Mohideen | Chief Medical Officer | Profile | |
| Kevin Trapp | Chief Commercial Officer | Profile |
About DBV Technologies Management Performance
The success or failure of an entity such as DBV Technologies often depends on how effective the management is. DBV Technologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of DBV management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the DBV management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. DBV TECHNOLOGIES operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 97 people.
The data published in DBV Technologies' official financial statements usually reflect DBV Technologies' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of DBV Technologies. For example, before you start analyzing numbers published by DBV accountants, it's critical to develop an understanding of what DBV Technologies' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of DBV Technologies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DBV Technologies' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in DBV Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of DBV Technologies SA. Please utilize our Beneish M Score to check the likelihood of DBV Technologies' management manipulating its earnings.
DBV Technologies Workforce Analysis
Traditionally, organizations such as DBV Technologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare DBV Technologies within its industry.DBV Technologies Manpower Efficiency
Return on DBV Technologies Manpower
| Revenue Per Employee | 67.2K | |
| Revenue Per Executive | 135.9K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 2.3M | |
| Working Capital Per Employee | 3.8M | |
| Working Capital Per Executive | 7.6M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DBV Technologies SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade DBV Stock refer to our How to Trade DBV Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Complementary Tools for DBV Stock analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |